Skip to main content

Advertisement

Log in

Pharmacologic Prevention and Treatment of Postpartum Hemorrhage

  • Obstetric Anesthesia (LR Leffert, Section Editor)
  • Published:
Current Anesthesiology Reports Aims and scope Submit manuscript

An Author Correction to this article was published on 28 April 2021

This article has been updated

Abstract

Purpose of Review

The purpose of this review is to synthetize the latest evidence on the pharmacological management of postpartum hemorrhage (PPH) and apply it to the clinical context.

Recent Findings

The incidence of PPH in the developed world is rising. Oxytocin and its analogue carbetocin remain the number one choice as first-line uterotonics for the prevention of PPH due to excellent clinical efficacy and a favorable side effect profile. Doses of oxytocin and carbetocin currently recommended for prophylaxis are in excess to that required for clinical efficacy. There is no robust evidence suggesting that one second-line uterotonic drug is superior to another. Tranexamic acid is safe and highly effective and should be administered both for cases at high risk for PPH as well as early in established hemorrhage.

Summary

Choosing a uterotonic drug strategy that uses the most appropriate agent in the clinical context at the minimal effective dose is essential for improving maternal safety and the quality of postpartum care.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Change history

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. •• WHO. WHO recommendations uterotonics for the prevention of postpartum haemorrhage. 2018. https://apps.who.int/iris/bitstream/handle/10665/277276/9789241550420-eng.pdf?ua=1. Accessed 30th December 2020. Global recommendations on PPH management with recommendations for high and low resource settings

  2. Say L, Chou D, Gemmill A, Tuncalp O, Moller AB, Daniels J, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health. 2014;2(6):e323–33.

    Article  PubMed  Google Scholar 

  3. Knight M, Callaghan WM, Berg C, Alexander S, Bouvier-Colle MH, Ford JB, et al. Trends in postpartum hemorrhage in high resource countries: a review and recommendations from the International Postpartum Hemorrhage Collaborative Group. BMC Pregnancy Childbirth. 2009;9:55.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Mehrabadi A, Liu S, Bartholomew S, Hutcheon JA, Kramer MS, Liston RM, et al. Temporal trends in postpartum hemorrhage and severe postpartum hemorrhage in Canada from 2003 to 2010. J Obstet Gynaecol Can. 2014;36(1):21–33.

    Article  PubMed  Google Scholar 

  5. Lutomski JE, Byrne BM, Devane D, Greene RA. Increasing trends in atonic postpartum haemorrhage in Ireland: an 11-year population-based cohort study. BJOG. 2012;119(3):306–14.

    Article  CAS  PubMed  Google Scholar 

  6. Begley CM, Gyte GM, Devane D, McGuire W, Weeks A. Active versus expectant management for women in the third stage of labour. Cochrane Database Syst Rev. 2011;11:CD007412.

    Google Scholar 

  7. •• Gallos ID, Papadopoulou A, Man R, Athanasopoulos N, Tobias A, Price MJ, et al. Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis. Cochrane Database Syst Rev. 2018;12:CD011689 Cochrane network metanalysis supports use of carbetocin.

    PubMed  Google Scholar 

  8. •• Heesen M, Carvalho B, Carvalho JCA, Duvekot JJ, Dyer RA, Lucas DN, et al. International consensus statement on the use of uterotonic agents during caesarean section. Anaesthesia. 2019;74(10):1305–19 International consensus statement provides evidence based guidance at caesarean delivery.

  9. NICE. Intrapartum care: care of healthy women and their babies during childbirth. Clinical Guideline 190. 2014.

  10. Gimpl G, Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. Physiol Rev. 2001;81(2):629–83.

    Article  CAS  PubMed  Google Scholar 

  11. Syntocinon®. Product information, Novartis Pharmaceuticals Australia Pty Ltd.

  12. Tang OS, Gemzell-Danielsson K, Ho PC. Misoprostol: pharmacokinetic profiles, effects on the uterus and side-effects. Int J Gynaecol Obstet. 2007;99(Suppl 2):S160–7.

    Article  CAS  PubMed  Google Scholar 

  13. Gizzo S, Patrelli TS, Gangi SD, Carrozzini M, Saccardi C, Zambon A, et al. Which uterotonic is better to prevent the postpartum hemorrhage? Latest news in terms of clinical efficacy, side effects, and contraindications: a systematic review. Reprod Sci. 2013;20(9):1011–9.

    Article  PubMed  Google Scholar 

  14. Schimmer BP, Parker KL. Contraception and pharmacotherapy of obstetrical and gynecological disorders. In: Brunton L, Chabner B, Knollman B, editors. Goodman & Gilman’s the Pharmacological Basis of Therapeutics. 12th ed. New York, NY: McGraw-Hill Medical; 2011.

    Google Scholar 

  15. Arrowsmith S, Wray S. Oxytocin: its mechanism of action and receptor signalling in the myometrium. J Neuroendocrinol. 2014;26(6):356–69.

    Article  CAS  PubMed  Google Scholar 

  16. Fuchs AR, Fuchs F, Husslein P, Soloff MS. Oxytocin receptors in the human uterus during pregnancy and parturition. Am J Obstet Gynecol. 1984;150(6):734–41.

    Article  CAS  PubMed  Google Scholar 

  17. Ryden G, Sjoholm I. Half-life of oxytocin in blood of pregnant and non-pregnant women. Acta Endocrinol. 1969;61(3):425–31.

    CAS  Google Scholar 

  18. Phaneuf S, Rodriguez Linares B, TambyRaja RL, MacKenzie IZ, Lopez BA. Loss of myometrial oxytocin receptors during oxytocin-induced and oxytocin-augmented labour. J Reprod Fertil. 2000;120(1):91–7.

    Article  CAS  PubMed  Google Scholar 

  19. Robinson C, Schumann R, Zhang P, Young RC. Oxytocin-induced desensitization of the oxytocin receptor. Am J Obstet Gynecol. 2003;188(2):497–502.

    Article  CAS  PubMed  Google Scholar 

  20. Balki M, Erik-Soussi M, Kingdom J, Carvalho JC. Oxytocin pretreatment attenuates oxytocin-induced contractions in human myometrium in vitro. Anesthesiology. 2013;119(3):552–61.

    Article  CAS  PubMed  Google Scholar 

  21. Balki M, Cristian AL, Kingdom J, Carvalho JC. Oxytocin pretreatment of pregnant rat myometrium reduces the efficacy of oxytocin but not of ergonovine maleate or prostaglandin F 2 alpha. Reprod Sci. 2010;17(3):269–77.

    Article  CAS  PubMed  Google Scholar 

  22. Petersson M. Cardiovascular effects of oxytocin. Prog Brain Res. 2002;139:281–8.

    Article  CAS  PubMed  Google Scholar 

  23. Thomas JS, Koh SH, Cooper GM. Haemodynamic effects of oxytocin given as i.v. bolus or infusion on women undergoing caesarean section. Br J Anaesth. 2007;98(1):116–9.

    Article  CAS  PubMed  Google Scholar 

  24. Butwick AJ, Coleman L, Cohen SE, Riley ET, Carvalho B. Minimum effective bolus dose of oxytocin during elective Caesarean delivery. Br J Anaesth. 2010;104(3):338–43.

    Article  CAS  PubMed  Google Scholar 

  25. G L. The National Institute for Clinical Excellence; The Scottish Executive Health Department; The Department of Health, Social Services and Public Safety: Northern Ireland. Why Mothers Die 1997–1999. The fifth report of the Confidential Enquiries into Maternal Deaths in the United Kingdom. London. 2001.

  26. Farina Z, Fawcus S. Oxytocin--ensuring appropriate use and balancing efficacy with safety. S Afr Med J. 2015;105(4):271–4.

    Article  CAS  PubMed  Google Scholar 

  27. Svanstrom MC, Biber B, Hanes M, Johansson G, Naslund U, Balfors EM. Signs of myocardial ischaemia after injection of oxytocin: a randomized double-blind comparison of oxytocin and methylergometrine during Caesarean section. Br J Anaesth. 2008;100(5):683–9.

    Article  CAS  PubMed  Google Scholar 

  28. Dansereau J, Joshi AK, Helewa ME, Doran TA, Lange IR, Luther ER, et al. Double-blind comparison of carbetocin versus oxytocin in prevention of uterine atony after cesarean section. Am J Obstet Gynecol. 1999;180(3 Pt 1):670–6.

    Article  CAS  PubMed  Google Scholar 

  29. Li C, Wang W, Summer SN, Westfall TD, Brooks DP, Falk S, et al. Molecular mechanisms of antidiuretic effect of oxytocin. J Am Soc Nephrol. 2008;19(2):225–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Shakhmatova EI, Osipova NA, Natochin YV. Changes in osmolality and blood serum ion concentrations in pregnancy. Hum Physiol. 2000;26(1):92–5.

    Article  CAS  Google Scholar 

  31. Bergum D, Lonnee H, Hakli TF. Oxytocin infusion: acute hyponatraemia, seizures and coma. Acta Anaesthesiol Scand. 2009;53(6):826–7.

    Article  CAS  PubMed  Google Scholar 

  32. • Adnan N, Conlan-Trant R, McCormick C, Boland F, Murphy DJ. Intramuscular versus intravenous oxytocin to prevent postpartum haemorrhage at vaginal delivery: randomised controlled trial. BMJ. 2018;362:k3546 Recent RCT comparing the most common methds of oxytocin administration.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Kirsch P. Oxytocin in the socioemotional brain: implications for psychiatric disorders. Dialogues Clin Neurosci. 2015;17(4):463–76.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Kroll-Desrosiers AR, Nephew BC, Babb JA, Guilarte-Walker Y, Moore Simas TA, Deligiannidis KM. Association of peripartum synthetic oxytocin administration and depressive and anxiety disorders within the first postpartum year. Depress Anxiety. 2017;34(2):137–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Prevention and Management of Postpartum Haemorrhage. BJOG: An Int J Obstet Gynaecol. 2017;124(5):e106-e49.

  36. Committee on Practice B-O. Practice Bulletin No. 183. 183: Postpartum Hemorrhage. Obstet Gynecol. 2017;130(4):e168–e86.

    Article  Google Scholar 

  37. Intrapartum care for healthy women and babies. NICE Clinical Guideline 190. London: National Institute for Health and Care Excellence; 2014.

    Google Scholar 

  38. Carvalho JC, Balki M, Kingdom J, Windrim R. Oxytocin requirements at elective cesarean delivery: a dose-finding study. Obstet Gynecol. 2004;104(5 Pt 1):1005–10.

    Article  CAS  PubMed  Google Scholar 

  39. Balki M, Ronayne M, Davies S, Fallah S, Kingdom J, Windrim R, et al. Minimum oxytocin dose requirement after cesarean delivery for labor arrest. Obstet Gynecol. 2006;107(1):45–50.

    Article  CAS  PubMed  Google Scholar 

  40. Torloni MR, Gomes Freitas C, Kartoglu UH, Metin Gulmezoglu A, Widmer M. Quality of oxytocin available in low- and middle-income countries: a systematic review of the literature. BJOG. 2016;123(13):2076–86.

    Article  CAS  PubMed  Google Scholar 

  41. Pickering K, Gallos ID, Williams H, Price MJ, Merriel A, Lissauer D, et al. Uterotonic drugs for the prevention of postpartum haemorrhage: a cost-effectiveness analysis. Pharmacoecon Open. 2019;3(2):163–76.

    Article  PubMed  Google Scholar 

  42. Onwochei DN, Van Ross J, Singh PM, Salter A, Monks DT. Carbetocin reduces the need for additional uterotonics in elective caesarean delivery: a systematic review, meta-analysis and trial sequential analysis of randomised controlled trials. Int J Obstet Anesth. 2019;40:14–23.

    Article  CAS  PubMed  Google Scholar 

  43. Voon HY, Shafie AA, Bujang MA, Suharjono HN. Cost effectiveness analysis of carbetocin during cesarean section in a high volume maternity unit. J Obstet Gynaecol Res. 2018;44(1):109–16.

    Article  PubMed  Google Scholar 

  44. • Widmer M, Piaggio G, Nguyen TMH, Osoti A, Owa OO, Misra S, et al. Heat-stable carbetocin versus oxytocin to prevent hemorrhage after vaginal birth. N Engl J Med. 2018;379(8):743–52 RCT demonstrates non-inferiority of heat stable carbetocin to oxytocin.

    Article  CAS  PubMed  Google Scholar 

  45. Leduc D, Senikas V, Lalonde AB. No. 235-active management of the third stage of labour: prevention and treatment of postpartum hemorrhage. J Obstet Gynaecol Can. 2018;40(12):e841–e55.

    Article  PubMed  Google Scholar 

  46. Hunter DJ, Schulz P, Wassenaar W. Effect of carbetocin, a long-acting oxytocin analog on the postpartum uterus. Clin Pharmacol Ther. 1992;52(1):60–7.

    Article  CAS  PubMed  Google Scholar 

  47. Atke A, Vilhardt H. Uterotonic activity and myometrial receptor affinity of 1-deamino-1-carba-2-tyrosine(O-methyl)-oxytocin. Acta Endocrinol. 1987;115(1):155–60.

    CAS  Google Scholar 

  48. Cole NM, Carvalho JC, Erik-Soussi M, Ramachandran N, Balki M. In vitro comparative effect of carbetocin and oxytocin in pregnant human myometrium with and without oxytocin pretreatment. Anesthesiology. 2016;124(2):378–86.

    Article  CAS  PubMed  Google Scholar 

  49. Mannaerts D, Van der Veeken L, Coppejans H, Jacquemyn Y. Adverse effects of carbetocin versus oxytocin in the prevention of postpartum haemorrhage after caesarean section: a randomized controlled trial. J Pregnancy. 2018;2018:1374150.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Nguyen-Lu N, Carvalho JC, Farine D, Seaward G, Ye XY, Balki M. Carbetocin at cesarean delivery for labour arrest: a sequential allocation trial to determine the effective dose. Can J Anaesth. 2015;62(8):866–74.

    Article  PubMed  Google Scholar 

  51. Khan M, Balki M, Ahmed I, Farine D, Seaward G, Carvalho JC. Carbetocin at elective cesarean delivery: a sequential allocation trial to determine the minimum effective dose. Can J Anaesth. 2014;61(3):242–8.

    Article  PubMed  Google Scholar 

  52. Drew T, Balki M, Farine D, Ye XY, Downey K, Carvalho JCA. Carbetocin at elective caesarean section: a sequential allocation trial to determine the minimum effective dose in obese women. Anaesth 2020:75;331–37. https://doi.org/10.1111/anae.14944.

  53. Zhang J, Bricker L, Wray S, Quenby S. Poor uterine contractility in obese women. BJOG. 2007;114(3):343–8.

    Article  CAS  PubMed  Google Scholar 

  54. Dell-Kuster S, Hoesli I, Lapaire O, Seeberger E, Steiner LA, Bucher HC, et al. Efficacy and safety of carbetocin given as an intravenous bolus compared with short infusion for caesarean section - double-blind, double-dummy, randomized controlled non-inferiority trial. Br J Anaesth. 2017;118(5):772–80.

    Article  CAS  PubMed  Google Scholar 

  55. Balki M, Erik-Soussi M, Ramachandran N, Kingdom J, Carvalho JC. The contractile effects of oxytocin, ergonovine, and carboprost and their combinations: an in vitro study on human myometrial strips. Anesth Analg. 2015;120(5):1074–84.

    Article  CAS  PubMed  Google Scholar 

  56. The carboprost or oxytocin postpartum haemorrhage effectiveness study. Available from: http://copestudy.uk/.

  57. Hofmeyr GJ, Gulmezoglu AM. Misoprostol for the prevention and treatment of postpartum haemorrhage. Best Pract Res Clin Obstet Gynaecol. 2008;22(6):1025–41.

    Article  PubMed  Google Scholar 

  58. Smith JM, Dimiti A, Dwivedi V, Ochieng I, Dalaka M, Currie S, et al. Advance distribution of misoprostol for the prevention of postpartum hemorrhage in South Sudan. Int J Gynaecol Obstet. 2014;127(2):183–8.

    Article  PubMed  Google Scholar 

  59. Kilpatrick AW, Thorburn J. Severe hypotension due to intramyometrial injection of prostaglandin E2. Anaesthesia. 1990;45(10):848–9.

    Article  CAS  PubMed  Google Scholar 

  60. Baduni N, Sanwal MK, Jain A. Acute pulmonary edema after intramyometrial prostodin. J Anaesthesiol Clin Pharmacol. 2011;27(2):275–7.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Chen FG, Koh KF, Chong YS. Cardiac arrest associated with sulprostone use during caesarean section. Anaesth Intensive Care. 1998;26(3):298–301.

    Article  CAS  PubMed  Google Scholar 

  62. Bilgin Z, Komurcu N. Comparison of the effects and side effects of misoprostol and oxytocin in the postpartum period: a systematic review. Taiwan J Obstet Gynecol. 2019;58(6):748–56.

    Article  PubMed  Google Scholar 

  63. • Dey T, Weeks AD. Identification, prevention and management of post-partum haemorrhage. Obstetr Gynaecol Reprodu Medi. 2020;30(8):231–41 Clear review of PPH management from the surgical perspective.

    Article  Google Scholar 

  64. Chong YS, Chua S, Shen L, Arulkumaran S. Does the route of administration of misoprostol make a difference? The uterotonic effect and side effects of misoprostol given by different routes after vaginal delivery. Eur J Obstet Gynecol Reprod Biol. 2004;113(2):191–8.

    Article  CAS  PubMed  Google Scholar 

  65. Zieman M, Fong SK, Benowitz NL, Banskter D, Darney PD. Absorption kinetics of misoprostol with oral or vaginal administration. Obstet Gynecol. 1997;90(1):88–92.

    Article  CAS  PubMed  Google Scholar 

  66. Khan RU, El-Refaey H. Pharmacokinetics and adverse-effect profile of rectally administered misoprostol in the third stage of labor. Obstet Gynecol. 2003;101(5 Pt 1):968–74.

    CAS  PubMed  Google Scholar 

  67. Vogel JP, Williams M, Gallos I, Althabe F, Oladapo OT. WHO recommendations on uterotonics for postpartum haemorrhage prevention: what works, and which one? BMJ Glob Health. 2019;4(2):e001466.

    Article  PubMed  PubMed Central  Google Scholar 

  68. de Groot AN, van Dongen PW, Vree TB, Hekster YA, van Roosmalen J. Ergot alkaloids. Current status and review of clinical pharmacology and therapeutic use compared with other oxytocics in obstetrics and gynaecology. Drugs. 1998;56(4):523–35.

    PubMed  Google Scholar 

  69. DM RH, JM R. Rang and Dale’s Pharmacology: Churchill Livingstone; 2011.

  70. Hollingsworth M, Edwards D, Miller M. Ergometrine--a partial agonist at 5-HT receptors in the uterus isolated from the oestrogen-primed rat. Eur J Pharmacol. 1988;158(1-2):79–84.

    Article  CAS  PubMed  Google Scholar 

  71. Spencer SPE, Lowe SA. Ergometrine for postpartum hemorrhage and associated myocardial ischemia: Two case reports and a review of the literature. Clin Case Rep. 2019;7(12):2433–42.

    Article  PubMed  PubMed Central  Google Scholar 

  72. van Dongen PW, de Groot AN. History of ergot alkaloids from ergotism to ergometrine. Eur J Obstet Gynecol Reprod Biol. 1995;60(2):109–16.

    Article  PubMed  Google Scholar 

  73. Liabsuetrakul T, Choobun T, Peeyananjarassri K, Islam QM. Prophylactic use of ergot alkaloids in the third stage of labour. Cochrane Database Syst Rev. 2018;6:CD005456.

    PubMed  Google Scholar 

  74. G. M. Ergonovine maleate and methylergonovine maleate. AHFS drug information. 2004.

  75. • Brenner A, Ker K, Shakur-Still H, Roberts I. Tranexamic acid for post-partum haemorrhage: what, who and when. Best Pract Res Clin Obstet Gynaecol. 2019;61:66–74 Detailed review of tranexamic acid.

    Article  PubMed  PubMed Central  Google Scholar 

  76. Ker K, Edwards P, Perel P, Shakur H, Roberts I. Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis. BMJ. 2012;344:e3054.

    Article  PubMed  PubMed Central  Google Scholar 

  77. Roberts I, Shakur H, Coats T, Hunt B, Balogun E, Barnetson L, et al. The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients. Health Technol Assess. 2013;17(10):1–79.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. •• Collaborators WT. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet. 2017;389(10084):2105–16 Global trial supporting use of traexamic acid for the prevention of PPH.

    Article  Google Scholar 

  79. Ducloy-Bouthors AS, Jude B, Duhamel A, Broisin F, Huissoud C, Keita-Meyer H, et al. High-dose tranexamic acid reduces blood loss in postpartum haemorrhage. Crit Care. 2011;15(2):R117.

    Article  PubMed  PubMed Central  Google Scholar 

  80. Shakur H, Beaumont D, Pavord S, Gayet-Ageron A, Ker K, Mousa HA. Antifibrinolytic drugs for treating primary postpartum haemorrhage. Cochrane Database Syst Rev. 2018;2:CD012964.

    PubMed  Google Scholar 

  81. Li B, Miners A, Shakur H, Roberts I, Collaborators WT. Tranexamic acid for treatment of women with post-partum haemorrhage in Nigeria and Pakistan: a cost-effectiveness analysis of data from the WOMAN trial. Lancet Glob Health. 2018;6(2):e222–e8.

    Article  PubMed  PubMed Central  Google Scholar 

  82. Weeks AD. Tranexamic acid for postpartum haemorrhage: a major advance. Lancet Glob Health. 2018;6(2):e132–e3.

    Article  PubMed  Google Scholar 

  83. Lecker I, Wang DS, Whissell PD, Avramescu S, Mazer CD, Orser BA. Tranexamic acid-associated seizures: causes and treatment. Ann Neurol. 2016;79(1):18–26.

    Article  CAS  PubMed  Google Scholar 

  84. Gungorduk K, Yildirim G, Asicioglu O, Gungorduk OC, Sudolmus S, Ark C. Efficacy of intravenous tranexamic acid in reducing blood loss after elective cesarean section: a prospective, randomized, double-blind, placebo-controlled study. Am J Perinatol. 2011;28(3):233–40.

    Article  PubMed  Google Scholar 

  85. Franchini M, Mengoli C, Cruciani M, Bergamini V, Presti F, Marano G, et al. Safety and efficacy of tranexamic acid for prevention of obstetric haemorrhage: an updated systematic review and meta-analysis. Blood Transfus. 2018;16(4):329–37.

    PubMed  PubMed Central  Google Scholar 

  86. Vasichko PE, Ireland KE, Boyd AR, Acosta OM, Ramsey PS. Use of tranexamic acid to prevent postpartum hemorrhage in women undergoing cesarean delivery: a meta-analysis. Obstet Gynecol. 2018;131:90S.

    Article  Google Scholar 

  87. Sentilhes L, Daniel V, Deneux-Tharaux C, Group TS, the Groupe de Recherche en Obstetrique et G. TRAAP2 - TRAnexamic acid for preventing postpartum hemorrhage after cesarean delivery: a multicenter randomized, doubleblind, placebo- controlled trial - a study protocol. BMC Pregnancy Childbirth. 2020;20(1):63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Sentilhes L, Winer N, Azria E, Senat MV, Le Ray C, Vardon D, et al. Tranexamic acid for the prevention of blood loss after vaginal delivery. N Engl J Med. 2018;379(8):731–42.

    Article  CAS  PubMed  Google Scholar 

  89. Gungorduk K, Asicioglu O, Yildirim G, Ark C, Tekirdag AI, Besimoglu B. Can intravenous injection of tranexamic acid be used in routine practice with active management of the third stage of labor in vaginal delivery? A randomized controlled study. Am J Perinatol. 2013;30(5):407–13.

    PubMed  Google Scholar 

  90. Hellgren M. Hemostasis during normal pregnancy and puerperium. Semin Thromb Hemost. 2003;29(2):125–30.

    Article  CAS  PubMed  Google Scholar 

  91. Shakur-Still H, Roberts I, Fawole B, Kuti M, Olayemi OO, Bello A, et al. Effect of tranexamic acid on coagulation and fibrinolysis in women with postpartum haemorrhage (WOMAN-ETAC): a single-centre, randomised, double-blind, placebo-controlled trial. Wellcome Open Res. 2018;3:100.

    Article  PubMed  PubMed Central  Google Scholar 

  92. Prentice CR. Basis of antifibrinolytic therapy. J Clin Pathol Suppl (R Coll Pathol). 1980;14:35–40.

    Article  CAS  Google Scholar 

  93. Goobie SM, Frank SM. Tranexamic acid: what is known and unknown, and where do we go from here? Anesthesiology. 2017;127(3):405–7.

    Article  PubMed  Google Scholar 

  94. Frimat M, Decambron M, Lebas C, Moktefi A, Lemaitre L, Gnemmi V, et al. Renal cortical necrosis in postpartum hemorrhage: a case series. Am J Kidney Dis. 2016;68(1):50–7.

    Article  PubMed  Google Scholar 

  95. • Patel S, Robertson B, McConachie I. Catastrophic drug errors involving tranexamic acid administered during spinal anaesthesia. Anaesthesia. 2019;74(7):904–14 Important paper highlighting dangers of tranexamic acid and potential neuraxial administration.

    Article  CAS  PubMed  Google Scholar 

  96. Xia Y, Griffiths BB, Xue Q. Tranexamic acid for postpartum hemorrhage prevention in vaginal delivery: a meta-analysis. Medicine (Baltimore). 2020;99(3):e18792.

    Article  PubMed  PubMed Central  Google Scholar 

  97. Gayet-Ageron A, Prieto-Merino D, Ker K, Shakur H, Ageron FX, Roberts I, et al. Effect of treatment delay on the effectiveness and safety of antifibrinolytics in acute severe haemorrhage: a meta-analysis of individual patient-level data from 40 138 bleeding patients. Lancet. 2018;391(10116):125–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Grassin-Delyle S, Semeraro M, Foissac F, Bouazza N, Shakur-Still H, Roberts I, et al. Tranexamic acid through intravenous, intramuscular and oral routes: an individual participant data meta-analysis of pharmacokinetic studies in healthy volunteers. Fundam Clin Pharmacol. 2019;33(6):670–8.

    Article  CAS  PubMed  Google Scholar 

  99. Diop A, Abbas D, Ngoc NTN, Martin R, Razafi A, Tuyet HTD, et al. A double-blind, randomized controlled trial to explore oral tranexamic acid as adjunct for the treatment for postpartum hemorrhage. Reprod Health. 2020;17(1):34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Orbach-Zinger S, Einav S, Yona A, Eidelman LA, Fein S, Davis A, et al. A survey of physicians' attitudes toward uterotonic administration in parturients undergoing cesarean section. J Matern Fetal Neonatal Med. 2018;31(23):3183–90.

    Article  PubMed  Google Scholar 

  101. Weale N, Laxton C. Prophylactic use of oxytocin at caesarean section: where are the guidelines? Anaesthesia. 2013;68(10):1006–9.

    Article  CAS  PubMed  Google Scholar 

  102. Monks DT, Palanisamy A. Intrapartum oxytocin: time to focus on longer term consequences? Anaesthesia. 2019;74(10):1219–22.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Thomas Drew.

Ethics declarations

Conflict of interest

The authors do not have any potential conflicts of interest to disclose.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Obstetric Anesthesia

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Drew, T., Carvalho, J.C.A. Pharmacologic Prevention and Treatment of Postpartum Hemorrhage. Curr Anesthesiol Rep 11, 37–47 (2021). https://doi.org/10.1007/s40140-021-00444-7

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40140-021-00444-7

Keywords

Navigation